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Abstract
Introduction: Economic models and computer simulation models have been used for assessing short-term 
cost-effectiveness of  interventions and modelling long-term outcomes and costs.  Several guidelines and 
checklists have been published to improve the methods and reporting.  This article presents an overview of  
published diabetes models with a focus on how well the models are described in relation to the considerations 
described by the American Diabetes Association (ADA) guidelines.
Methods: Relevant electronic databases and National Institute for Health and Care Excellence (NICE) 
guidelines were searched in December 2012.  Studies were included in the review if  they estimated lifetime 
outcomes for patients with type 1 or type 2 diabetes. Only unique models, and only the original papers 
were included in the review.  If  additional information was reported in subsequent or paired articles, then 
additional citations were included. References and forward citations of  relevant articles, including the 
previous systematic reviews were searched using a similar method to pearl growing.  Four principal areas 
were included in the ADA guidance reporting for models: transparency, validation, uncertainty, and diabetes 
specific criteria.
Results: A total of  19 models were included.  Twelve models investigated type 2 diabetes, two developed 
type 1 models, two created separate models for type 1 and type 2, and three developed joint type 1 and type 
2 models. Most models were developed in the United States, United Kingdom, Europe or Canada.  Later 
models use data or methods from earlier models for development or validation. There are four main types 
of  models: Markov-based cohort, Markov-based microsimulations, discrete-time microsimulations, and 
continuous time differential equations.  All models were long-term diabetes models incorporating a wide 
range of  compilations from various organ systems. In early diabetes modelling, before the ADA guidelines 
were published, most models did not include descriptions of  all the diabetes specific components of  the 
ADA guidelines but this improved significantly by 2004. 
Conclusion: A clear, descriptive short summary of  the model was often lacking. Descriptions of  model 
validation and uncertainty were the most poorly reported of  the four main areas, but there exist conferences 
focussing specifically on the issue of  validation.  Interdependence between the complications was the least 
well incorporated or reported of  the diabetes-specific criterion.
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Introduction
Rationale
Economic models have been used for assessing short-term cost-effectiveness of  interventions as well as 
modelling long-term outcomes and lifetime costs in almost all disease areas.  Decision makers often turn 
to computer simulation models to predict the effect of  treatments in the longer term.  These models can 
be used to address a variety of  clinical outcomes and questions, and also assess new treatment strategies. 
Although clinical trials are excellent sources of  information on effectiveness of  treatments, they are only 
applicable to the population recruited, do not account for all characteristics of  a population, and they tend 
to be short timescales.1 This means that economics models are useful sources of  information by providing 
estimates of  the long-term effects and costs of  new interventions.
Several guidelines and checklists have been published to improve the methods and reporting of  economic 
models.2-5 Philips et al3 performed a systematic review to identify and summarise all guidelines that were 
available for assessing quality of  decision-analytic models. They created a checklist for critically appraising 
decision-analytic models for Health Technology Assessment (HTA), based on the format by Sculpher et 
al.4 The checklist suggests that models should clearly describe three major areas: structure such as clear 
statement of  problems/objective, rationale for the structure, assumptions, comparisons, model types, time 
horizon, disease states and cycle lengths; the data used to develop and populate the model including how 
data was identified, modelled, and incorporated into the model, and assessing uncertainty; and consistency, 
meaning whether the model is performing the way it was intended to perform, both internally (by testing 
the mathematical logic of  the model during development to fix errors) and externally (whether the results 
of  the model are consistent with information contained in relevant primary research studies).  
Other guidelines suggest that additional characteristics should be considered when assessing the quality of  
a model.6,7 These include: clinical relevance, encompassing all important facets of  the disease of  interest; 
transparency, details of  model structure and assumptions are provided with clear data sources; reproducibility, 
results of  the model can be reproduced by an independent researcher; interpretability, results are clear and 
can be easily interpreted; and exploration of  analytical ability and uncertainty such as methodological, 
structural, and data uncertainty, including heterogeneity and parameter uncertainty.   
Recently a series of  seven papers were published which updated the recommendations for best practices. 
The series provides a series of  recommendations for each stage of  model development, providing helpful 
suggestions on assessing the model for developers, reviewers, and those who report the results of  models 
or use models to make decisions.  The series provides best practice advice and recommendations on five 
main areas: model conceptualisation; implementation of  specific types of  model, including state-transition 
models (cohort or individual), discrete-event simulation, and dynamic transmission models; dealing with 
uncertainty and parameter estimation; validity and reporting models transparently.8-14 
However, in addition to generic advice for developing, assessing and reporting of  economic models, there 
are often disease specific considerations that should be included in the model development. One area 
where economic models have been used widely is diabetes. Diabetes is a chronic and complex disease 
with increased risks of  cardiovascular complications in addition to diabetes specific complications. The 
prevalence and financial cost of  diabetes is rising worldwide15,16, meaning that understanding and accurately 
assessing the costs and effectiveness of  healthcare delivery in diabetes is of  clear importance to health 
services.  
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In 2004, the American Diabetes Association (ADA) convened a work group of  diabetes modellers to 
create standardised guidelines that future modellers can use to ensure their models are accurate, useful and 
reliable.17 Along with the main considerations for models, they work group all determined a list of  diabetes-
specific requirements for the models.  
There are several diabetes models in existence that have been included in previous reviews.  One review18 
focussed on assessing models used in drug treatment cost-effectiveness analysis and the treatment effects 
that are incorporated into the model. The authors focussed on the model’s ability to incorporate the costs and 
benefits associated with different drug treatment alternatives.  This authors found that most models share 
common data sources and modelling approaches, and differed in terms of  interventions and complications 
evaluated.  They conclude that models should be reported in more detail in order to make them more 
transparent by including assumptions, data and statistical methods used, and should aim to include a wider 
range of  treatment outcomes relating to both the effects of  diabetes and its complications, and also side 
effects of  treatments investigated.  
Tarride et al19 provide an overview of  models focussing on the details of  the model itself  such as type, 
structure, data sources, assumptions, validations, presentation or results, and treatment of  uncertainty. 
Similar to Yi et al, the authors of  this review found that most models used similar model types and data 
sources, but differed in the complications that were include in the model. The authors conclude that models 
could be enhanced if  they were able to cope with both first- and second-order uncertainty.
Neither of  the previous reviews assessed the quality of  the reporting of  the model in regards to the guidelines 
set out by ADA. This review identifies and critically appraises diabetes simulation prediction models used 
to calculate health economic outcomes.  Specifically, this article presents an overview of  published diabetes 
models with a focus on how well the models are described in relation to the considerations described by 
the ADA guidelines.  
Methods
ADA Guidance
The American Diabetes Association are aware that decision makers are turning more to computer modelling 
in order to make decision on health care for those with diabetes. Models can be very powerful decision 
making tools if  they are properly constructed, validated and applied.  Therefore, a work group of  diabetes 
modellers was convened to create standardised guidelines that future modellers can use to ensure their 
models are accurate, useful, reliable and reproducible, and to reassure model users of  its quality.17
The workgroup determined there were three main considerations. First, models should be transparent 
by providing complete descriptions of  the model’s structure including inputs, equations, algorithms, 
assumptions and data sources.  If  the model is based on previously published model, changes and additions 
should be described in adequate detail.  Second, authors should report the level to which a model was 
validated to allow readers to assess whether predictions made by the model are accurate, this can include 
internal validation (reproduces results of  the studies that are used to develop the model) and external 
validation (reproduces results of  studies that were not used to develop the model). Finally, methods of  
assessing uncertainty should be described. Five types are listed, including ignorance, known variability, 
statistical variability, Monte Carlo variability and uncertainty from the model design. Uncertainty should 
be address through sensitivity analysis, averaging over multiple simulations or seek results from multiple 
models to ensure accuracy of  results.
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In addition to these, the ADA workgroup also list seven diabetes-specific requirements for models: long-term 
time horizons to allow complications to occur at a sensible time but also include mortality as a competing 
risk; include complications for multiple organ systems and interdependence between complications; include 
treatment effects since they can affect a diverse range of  outcomes; should include both life-expectancy and 
quality of  life measures; select the perspective of  the model carefully and explicitly state it in the analysis; 
be aware that there is a delay between onset and diagnosis; developers should be specific about the criteria 
used to diagnose  and classify diabetes since the diagnostic criteria have changed over time.  The final two 
requirements were not investigated in this review since we were interested in models predicting lifetime 
outcomes post-diagnosis.
Literature Review
The National Health Service Economic Evaluation database (NHS EED), Ovid, MEDLINE, and EMBASE 
were searched in December 2012 to identify possibly relevant articles.  A combination of  medical subject 
headings (MESH) and relevant keywords were used.  Search terms were combined with Boolean operators 
OR and AND. These included terms for the disease area (diabet$, diabetes, diabetes mellitus), study 
type (analys$, evaluat$, model$), type of  model (predict$, simulate$, lifetime, computer simulation), and 
incorporating health economic components (cost-effectiv$, cost-utility, life-years gained, quality-adjusted 
life-year, QALY, economic$, economic evaluation, cost$).
Studies were included in the review if  they estimated lifetime outcomes for patients with type 1 or type 2 
diabetes. All types of  models were included. Studies were excluded if  they were clinical studies, cost or cost-
effectiveness studies only (i.e. not simulation studies), non-diabetes related, or if  title identified the article as 
a screening or preventative model.  Studies were further excluded if  they only modelled one type of  diabetes 
complication (e.g. retinopathy), or only a subgroup of  patients (e.g. overweight people with diabetes).  The 
search was not restricted by date or language.  
Titles and abstracts were screened to identify relevant publications.  Only unique models were included in the 
review.  If  multiple papers reported using a particular model, the original paper was included in the review. 
However, for models where additional information was reported in subsequent or paired articles, then 
the additional citations were also included.  Further to the electronic database searching, NICE guidelines 
were also searched.  References and forward citations of  relevant articles, including the previous systematic 
reviews were also searched using a method similar to the pearl growing method.20
A data extraction form was created in Excel.  In order to assess each models’ reporting of  the ADA 
guidelines the following details were collected: model aims/objectives; type of  diabetes; model structure 
and simulation technique; data sources for patient data, costs, utilities, and methodologies; modelled 
complications/events; and outcomes and outputs from the model, such as life expectancy, QALY.  These 
details were collected to assess model transparency, and to assess how the model incorporated the additional 
diabetes-specific considerations as suggested by the ADA guidelines.
Results
Search results
Figure 1 provides an overview of  the number of  studies identified, included, excluded and reasons for 
exclusion.  In total 2389 citations were identified from electronic citation searching, of  which 2341 were 
excluded based on title and abstract.  Reference searching proved to be more efficient at identifying relevant
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articles due to that vast number of  economic evaluations performed in diabetes research.  A total of  97 
citations were extracted for full text review from electronic citation searching, and an additional 52 articles 
identified from forward citation searching and reference searching.  Models that included a screening 
component were excluded from this review.  However, models that used or extended the post-diagnosis 
component of  a screening model in order to create a new model21, 22 were included.  
After excluding articles based on the criteria described, a total of  28 articles were considered relevant to the 
review.  This number does not represent the number of  identified models but the number of  articles that 
describe the models, including companion and paired articles which describe validation, methodology etc. 
After reviewing and grouping the articles, a total of  19 models were identified.
Figure 1. Flow Chart of  Publications Selection and Exclusion from the Review
Study Characteristics, Summary of  Studies
Table 1 provides a description of  the models included in the review.  As per the inclusion criteria, the models 
main aims were to evaluate therapies and interventions by predicting future medical events over a patient’s 
lifetime.  Twelve models investigated type 2 diabetes23-34, two developed type 1 models35, 36, two created 
separate models for type 1 and type 237, 38, and three developed joint type 1 and type 2 diabetes models.39-41 
The majority of  models were developed either in the United States (9 models) or the United Kingdom (5 
models), with the others developed elsewhere in Europe or Canada. The majority of  later models use either 
data or methods from earlier models for development or validation.
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There are four main types of  models that were reviewed: five were Markov-based cohort models23,26,32,33,37,38; 
six were Markov-based microsimulations25,29,34-36,41; five were discrete-time microsimulations using risk 
equations to determine events24,27,28,30,40; two models were a combination of  Markov and discrete-time risk 
equations31,32; and one model used continuous time differential equations.39 A discrete-time simulation, also 
known as time-slicing, models the progression through time in which a constant time step is adopted.42 The 
model then assesses which events have happened at the end of  each time step (or cycle).  Multiple events 
can occur in each cycle until death.  Markov-type models also, typically, use discrete-time steps.43 Markov 
models are state-transition models that assess the probabilities of  transition to determine if  a patient has 
moved from one state to another at the end of  each cycle.  The main assumption around Markov models 
is that it is memoryless.  In other words, the transition to another state relies solely on the current state. 
However, techniques have been developed to mimic memory in these types of  models.44  Markov models 
can be analysed using a cohort of  patients, or following the path of  an individual.  
Of  the models, eleven used Monte Carlo techniques24,25,27-30,32,34,35,40,41, five did not23,33,37,39,45, and three were 
unclear in their descriptions26,31,36.  Monte Carlo simulation is used in order to provide a more stable estimate 
of  outcomes or probabilistic answers to the simulation. 
ADA Guidelines
Table 2 provides a coding system for adequacy of  reporting of  the ADA criteria.  In order for models to 
be reproducible, transparency is a key component of  reporting a model.  When assessing the transparency 
of  the reporting of  the models, we determined if  a model diagram was reported along with equations, 
transition probabilities or other information relating to determination of  events or transition between 
states.  Nine models24,27-30,33,34,36,41 provided a model diagram and a description of  further details needed 
to determine events or transitions, thereby providing adequate transparency in the model. A further six 
models23,26,32,35,37,45 provide a model diagram in detail but not all the details required to determine events/
transitions; two models31,39 provide diagrams for some events but not a full diagram; and two models25,40 did 
not provide a model diagram in the paper.  
Internal validation of  models is reported in over half  of  the models reviewed, either within the original 
paper or as a companion article. External validation was less frequently reported alongside the original 
descriptive paper, though many have been validated in follow-up articles years after first publication.  
ADA guidelines suggest different types of  uncertainty that can be assessed, and suggestions on how to 
assess them.  They advise assessing ignorance and known variability through sensitivity analysis, of  which all 
models reported in some way.  The majority of  models reported both performing sensitivity and providing 
results within the article, with only five exceptions: one model24 was unclear in their descriptions of  sensitivity 
analysis by stating it could be performed but did not detail what variables or parameters could be varied or 
report the results; two models state that sensitivity analysis was performed but did not report the results23,40; 
one did not mention sensitivity analysis28; and one model39 reported that uncertainty was dealt with through 
extensive validation, making it unclear how uncertainty was dealt with.  Statistical variability (parameters 
derived from statistical analysis) was less well reported.  ADA suggests either reporting confidence intervals 
for the parameter, confidence intervals for model results that depend on that parameter, or sensitivity 
analysis.  However, for most models confidence intervals were not reported for the parameter, or sensitivity 
analyses performed around the parameters. Over half  of  the models reported the use of  Monte Carlo 
techniques for dealing with uncertainty.
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Table 2. Criteria Defined by the ADA in Reporting a Diabetes Prediction Model
++ reported well; + partially reported; ? unclear reporting; - not reported
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The inclusion criteria determined that all models would be lifetime models. However, some do not report 
for how long the model is run, or cap the model at a particular age. For example, the Cardiff  model stops 
after 20 years, but can be extended to 40 years if  further information is provided to the model.31 Other 
models do not provide an estimate of  the end point for the model, or for how long it can conceivably 
run.34,39,40  In early models, competing risks were not well reported or incorporated.  However, only three 
models did not report any incorporation of  competing risks.25,29,35
Interdependence is the least well reported of  the diabetes specific criteria. The Archimedes model in 2003 
and UKPDS in 2004 were the first models to explicitly report that interdependence was modelled between 
the complications.  Neither of  these models were Markov-based models, where interdependence may be 
difficult to incorporate between the different states. However, most Markov-based microsimulation models 
after this also included interdependence between types of  events in some way, such as tracker variables. 
UKPDS, being the first discrete-time microsimulation, incorporated interdependence through the use of  
indicator variables. Consequently, many later models, such as the JADE model and ECHO amongst others, 
incorporated event equations from the UKPDS model, and so incorporated interdependence.
All models include retinopathy or blindness, and nephrology, renal failure or end-stage renal disease (ESRD) 
as possible complication events. All but one model includes neuropathy or amputation.33 Eastman29 and 
GDM24 include a CVD module where states included yes or no but Accuism45 was the first to incorporate 
specific CVD complications as modules or events in the model. Following this, all models included both 
micro- and macrovascular complications.  
Length of  life is reported in all but one of  the models, which instead reported duration of  treatment to 
prevent 1 year of  blindness.33 One model did not report QALY45; two studies were unclear in their reporting 
if  QALYs or QALEs could be calculated using the model23,39; and one reported QALYs in a companion 
paper.46 Perspective of  costs was not often reported, mainly because the paper reports the model description 
and method and costs, QALYS and perspective are reported in application papers published after the initial 
article.  
Discussion
This article aimed to critically appraise how well the models are described in relation to the criteria described 
by the ADA guidelines, which included four main areas: transparency, validation, uncertainty and diabetes 
specific criteria.  In total, 19 models were identified which were described in over 28 articles.  The majority 
of  models provided adequate descriptions of  the models, although a clear, descriptive short summary 
of  the model was often lacking.  In early diabetes modelling, before the ADA guidelines were published, 
the majority of  models did not include descriptions of  all the diabetes specific components of  the ADA 
guidelines.  However, by 2004 most models were reporting these components.  All models were long-term 
diabetes models with the majority providing estimates of  length and quality of  life, and incorporating a 
wide range of  compilations from various organ systems.  However, descriptions of  model validation and 
uncertainty were the most poorly reported of  the four main areas, with interdependence between the 
complications being the least well incorporated or reported of  the diabetes-specific criterion.  These areas 
will be discussed further.
Validation
Model transparency does not indicate that a model is accurate.  Therefore, it is important that a model 
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is also valid. Validation aims to determine if  a model accurately calculates the outcomes of  interest.10 Five main 
types of  validation are identified: face validity, verification (internal validity), cross validity, external validity and 
predictive validity. The ADA guidelines recommend describing internal validity and external validity of  a model. 
Internal validity is the extent to which a model reproduces the results of  the studies that are used to develop 
the model.17 In other words, ensuring that the model behaves as intended and has been implemented 
correctly.10 The ISPOR-SMDM Modelling Good Research Practices Task Force recommend that all model 
should be subjected to rigorous verification and the methods used should be described in the non-technical 
documentation of  the model. The majority of  models in this review report internal validation either within 
the original paper or as a companion paper. The authors often only state that the model was validated against 
the data from which it was created but do not provide specific details. However, this does not mean that 
further details are not available elsewhere, such as a non-peer reviewed report or requested from authors.
External validation should show if  the model can reproduce results of  studies that were not used to develop 
the model and involves three steps: identifying data sources, running the model and comparing the results. 
Models often draw on the same data sources in order to populate or create the models.  For example, the 
UKPDS dataset47 and risk equations28 are used for creation by all but three models, two of  which were 
published before the UKPDS trial29,35, and one that used in for external validation.33 This poses a problem 
for externally validating the models. Due to the lack of  appropriate, independent data at the time of  model 
creation, external validation often occurs years after the model was first reported, for example the CDC 
model.48 The UKPDS trial was one of  very few large trials conducted that could be used for validation, but 
if  the majority of  the other models already use the UKPDS risk equations in their construction then this 
would exclude it from being used for independent external validation. Another complication in the effort 
to externally validate a model occurs when older datasets are not necessarily relevant today given new drugs 
on market, lifestyle interventions and better standard of  living/life expectancy. Additionally, validation of  a 
model using one data source does not necessarily make it valid, as it would need to be tested using various 
patient groups, timescales and other factors.10,49 However, the Mount Hood diabetes challenge (http://
www.mthooddiabeteschallenge.org/) has been instrumental in encouraging external validation (and cross 
validation) by issuing ‘short term’ challenges designed to look at how models predict trials that have been 
published after model development. The Mount Hood Diabetes Challenge provides a platform to externally 
validate models. The conference brings together diabetes researchers to help solve the challenge of  treating 
diabetes, discuss the modelling of  diabetes progression and diabetes complications.  Hypothetical modelling 
challenges are provided to modelling groups in advance of  the conference, and the results are compared 
and examined during the conference.
Uncertainty
Uncertainty analysis aims to assess the confidence in a chosen course of  action and determine the value 
of  additional information to inform a decision.11 All models included in the review assessed uncertainty 
through some means, either by deterministic sensitivity analysis, probabilistic sensitivity analysis or Monte 
Carlo simulations. However, Expected Value of  Perfect Information (EVPI) and Expected Value of  Perfect 
Parameter Information (EVPPI) were not assessed or reported by any of  the models. The Archimedes 
model39 aimed to assess uncertainty through extensive validation, but the authors concede that this approach 
introduces further error and bias since trials are subject to random and systematic errors. 
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The structure of  the model will determine whether Monte Carlo error (of  stochastic error) can be ignored.11 
For individual patient simulation, such as the discrete-time models or Markov-based microsimulations, 
Monte Carlo error needs to be eliminated before addressing parameter uncertainty.  Of  the models included 
in this review, five were Markov-based cohort models, which do not require elimination of  Monte Carlo 
error.  This means that the model articles did not report the use of  Monte Carlo techniques, as it was not 
required to assess uncertainty.
Bagust et al23 argues against the use of  microsimulation and Monte Carlo simulation.  They argue that in 
long-term models using these techniques introduces further uncertainty in the model due to the assumptions 
around the source and nature of  variations. Also, the authors believe that any confidence regions obtained 
will offer little information due to being too wide. The authors suggest that the only practical approach to 
assessing uncertainty is to perform selective sensitivity analysis. However, recent guidelines11 suggest that 
selectively varying the inputs of  the model to assess the changes on the outputs should only be used as a 
measure of  sensitivity and does not represent uncertainty in the parameters.
Interdependence
Previous to 2003 (and therefore the publication of  the ADA guidelines) many models did not include 
adequate descriptions of  the diabetes specific requirements as outlined by ADA.  Interdependence between 
diabetes endpoints was least well reported or incorporated by the models.  However, the type of  model used 
may be a possible explanation for this.  Twelve models were Markov based models (six microsimulation), 
five were discrete-time, one was a combination of  discrete-time and Markov-based modelling, and the last 
used continuous time differential equations.  The different modelling approaches have different strengths 
and limitations.  
Cohort Markov models simplify the model into a discrete number of  states and minimise computing time 
by simulating a cohort and not individual patients.  Markov microsimulation models allow variation between 
individual patients to be modelled.  Markov models by definition do not carry a history of  events or of  
time spent in previous states.  This can be overcome by incorporating temporary or tunnel states, which can 
only be visited in a specific sequence44; or tracker variables, which update when an event has taken place.43 
Tracker variables will generally only be incorporated when the model is a microsimulation meaning that a 
record of  that patient’s movements may be recorded.  
Discrete-time models allow a larger number of  possible events to be included and can more easily incorporate 
interdependence between types of  events.  This was achieved by including an indicator variable that would 
update when an event occurred.  Three discrete-time models were described as discrete-event models within 
the article.  However, each of  these models actually used a discrete-time step in the simulation.  A discrete-
time simulation, also known as time-slicing, models the progression through time in which a constant time 
step is adopted.42 The model then assesses which events have happened at the end of  each time step.  In 
contrast, in a discrete-event simulation, the simulator need not explicitly represent the state of  the system 
at non-event times and can therefore move from one event to the next without simulating all time-steps in 
between.9,50 None of  the models included in this review utilise a discrete-event simulation structure. 
Continuous-time differential equations have many advantages, including preserving the continuous nature 
of  risk factors, and incorporating this into interactions between comorbidities, complications and disease. 
Thus interdependence is achieved between all disease, complications and comorbidities included in the 
model.  However, due to the complex nature of  the more advanced mathematics used, the model is less 
transparent due to fewer people having the training and knowledge to use these models.39
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Conclusions
After the publication of  the ADA guidelines, several models reference the guidelines and work towards 
better reporting based on them.   The guidelines themselves do not take into account that some requirements 
are unnecessary for inclusion in the model.  For example, Markov-based cohort models do not require the 
elimination of  Monte Carlo error and so this will not be reported.  Bagust and McEwan49 warn that strictly 
following the guidelines may mislead users into believing that the models are accurate and reliable.   They 
state that models are only a tool to guide decision makers and not objective evidence.  
This is the first review to assess diabetes model on how adequately published diabetes models report on 
the criteria set out by the ADA guidelines for diabetes modelling.  Diabetes modelling is still in its relative 
infancy with the first major model published in 1996.  As more models have been developed, the quality of  
reporting of  the model has improved, but more emphasis should be placed on including a clear, descriptive 
short summary of  the model; reporting the validation procedures; the assessment of  uncertainty in models; 
and incorporating interdependence between complications.
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